Navigation Links
PAREXEL Reports First Quarter Fiscal Year 2008 Financial Results
Date:10/24/2007

", "plans", "expects", "intends", "appears", "estimates", "projects", "targets" and similar expressions are also intended to identify forward-looking statements. The forward-looking statements in this release involve a number of risks and uncertainties. The Company's actual future results may differ significantly from the results discussed in the forward- looking statements contained in this release. Important factors that might cause such a difference include, but are not limited to, risks associated with: actual operating performance; actual expense savings and other operating improvements resulting from recent restructurings; the loss, modification, or delay of contracts which would, among other things, adversely impact the Company's recognition of revenue included in backlog; the Company's dependence on certain industries and clients; the Company's ability to win new business, manage growth and costs, and attract and retain employees; the Company's ability to complete additional acquisitions and to integrate newly acquired businesses or enter into new lines of business; the impact on the Company's business of government regulation of the drug, medical device and biotechnology industry; consolidation within the pharmaceutical industry and competition within the biopharmaceutical services industry; the potential for significant liability to clients and third parties; the potential adverse impact of health care reform; and the effects of exchange rate fluctuations and other international economic, political, and other risks. Such factors and others are discussed more fully in the section entitled "Risk Factors" of the Company's Annual Report on Form 10-K for the period ended June 30, 2007 as filed with the SEC on August 27, 2007, which "Risk Factors" discussion is incorporated by reference in this press release. The forward-looking statements included in this press release represent the Company's estimates as of the date of this release. The Company specifically di
'/>"/>
SOURCE PAREXEL International Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. TomoTherapy reports 86% revenue jump, $131M net loss in Q1
2. Sonic Foundry reports GAAP loss as Q2 revenues rise
3. Fiserv reports $113.5 million in Q1 profit
4. Third Wave reports net loss of $18.9M for 2006
5. Musicnotes reports 45 percent growth in 2006
6. Sonic Foundry reports net loss, higher revenue
7. Sonic Foundry reports first cash-positive quarter
8. Merge Healthcare reports $10.8M net loss in Q3
9. Third Wave reports $5.2M third quarter loss
10. Merge Healthcare appoints new CEO, reports $215 million Q2 loss
11. Merge files financial reports by market opening
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... 29, 2014 Three Lawrence Livermore ... Hydrogen Production R&D Award for their ... water using sunlight. , Shared with collaborators from ... University of Nevada, Las Vegas (UNLV), the award ... of photoelectrochemical solar-hydrogen production and corrosion processes. , ...
(Date:8/28/2014)... August 28, 2014 SPIE Fellow Glenn ... and Optical Science and Director of the Center for ... Carolina at Charlotte, and co-founder and Chairman of the ... as the 2015 Vice President of SPIE, the international ... Philip Stahl announced recent election results at the Annual ...
(Date:8/28/2014)... A new research platform uses a ... tiny structures undergoing stress and heating, an ... designs for microelectronics and batteries., This new ... about how heating and the surface stress ... Researchers have discussed the merits of surface-stress ...
(Date:8/28/2014)... Aug. 28, 2014  Next month, executives from clinical trial ... industry events beginning with Patient-Centered Clinical Trials 2014 , ... Boston , September 4-5. Patient recruitment experts ... Aaron Fleishman will share insights on the benefits of ... of tactics – from media to mobile apps – can ...
Breaking Biology Technology:Livermore Team Awarded for Hydrogen Production Research 2Glenn Boreman, UNC Professor and Plasmonics Co-Founder, Elected to SPIE Presidential Chain 2New analytical technology reveals 'nanomechanical' surface traits 2New analytical technology reveals 'nanomechanical' surface traits 3BBK Worldwide Leads Sessions at Key September Events 2
... Webcast on Wednesday, June 17 at 8:30 a.m. Eastern Time ... Savient Pharmaceuticals, Inc. (Nasdaq: SVNT ) announced today ... and Drug Administration (FDA) recommended by a vote of ... uricase enzyme, be granted marketing approval by the FDA for ...
... ... in a dynamic and unpredictable world at Wharton Leadership Conference. , ... Philadelphia, PA (Vocus) June 16, 2009 -- As the ... is well-positioned to deliver dynamic innovations to meet the evolving markets demand because “change is ...
... , , - Dosimetry Study Results Show Greater ... Normal Organs - , , - All Patients in the ... Time for Recurrent GBM Patients - , , TORONTO and ... PPHM ) today reported that researchers will present data at the ...
Cached Biology Technology:FDA Appointed Arthritis Advisory Committee Recommends U.S. Food and Drug Administration Approval for KRYSTEXXA(TM) for Refractory Chronic Gout 2FDA Appointed Arthritis Advisory Committee Recommends U.S. Food and Drug Administration Approval for KRYSTEXXA(TM) for Refractory Chronic Gout 3FDA Appointed Arthritis Advisory Committee Recommends U.S. Food and Drug Administration Approval for KRYSTEXXA(TM) for Refractory Chronic Gout 4Leading for Growth in the New Economic Reality Includes Vision and Innovation 2Leading for Growth in the New Economic Reality Includes Vision and Innovation 3Data Presented at Society of Nuclear Medicine 2009 Annual Meeting Supports Potential of Peregrine's Cotara(R) for the Treatment of Brain Cancer 2Data Presented at Society of Nuclear Medicine 2009 Annual Meeting Supports Potential of Peregrine's Cotara(R) for the Treatment of Brain Cancer 3Data Presented at Society of Nuclear Medicine 2009 Annual Meeting Supports Potential of Peregrine's Cotara(R) for the Treatment of Brain Cancer 4Data Presented at Society of Nuclear Medicine 2009 Annual Meeting Supports Potential of Peregrine's Cotara(R) for the Treatment of Brain Cancer 5Data Presented at Society of Nuclear Medicine 2009 Annual Meeting Supports Potential of Peregrine's Cotara(R) for the Treatment of Brain Cancer 6
(Date:9/1/2014)... Conventional wisdom has long held that corals ... reefs are passive organisms that rely entirely ... as nutrients and oxygen. But now scientists at ... in Israel have found that they are far ... into turbulent patterns that greatly enhance their ability ...
(Date:9/1/2014)... (September 1, 2014, 10:20 AM EDT) It may ... low-calorie foods over unhealthy higher-calorie foods, according to new ... Nutrition Research Center on Aging (USDA HNRCA) at Tufts ... in the journal Nutrition & Diabetes , a ... that it is possible to reverse the addictive power ...
(Date:9/1/2014)... electron microscopy revealed the presence of tiny blob-like structures ... scientists still don,t know what they do even ... to be crucial to the life of a cell, ... treatment., In the Journal of Cell Biology , ... various backgrounds, from biophysics to cell biology, to focus ...
Breaking Biology News(10 mins):Nature's tiny engineers 2Nature's tiny engineers 3Training your brain to prefer healthy foods 2Scientists call for investigation of mysterious cloud-like collections in cells 2
... scientists have received new funding for a research program ... economically feasible. The project is based on the serendipitous ... fish cages in Puerto Rico by the thousands. The ... fascinating habits such as their tendency to crawl in ...
... mussels and oysters are important vehicles for the ... undercooked. Vibrio species, including human pathogens, are particularly ... even after cleaning procedures, thus representing a potential ... are well known to affect the persistence of ...
... during the summer in Alaska waters, is one of the ... in the 1800s has now left us with only a ... different species from right whales seen in the North Atlantic ... areas and ecological parameters critical to the survival of this ...
Cached Biology News:New project aims to make large-scale lobster farms feasible 2New project aims to make large-scale lobster farms feasible 3Edible bivalves as a source of human pathogens: signals between vibrios and the bivalve host. 2Habitat use by North Pacific right whales, Eubalaena japonica, in the Bering Sea and Gulf of Alaska 2
... is for 2-D separations. The cell has a ... II xi multi-cell can be customized for several ... and cooling system. The PROTEAN II xi multi-cell ... XL multi-cell for a wider format that accommodates ...
... depletion cocktail is tailored to ... suspensions of rat spleen cells. ... StemSep (or compatible 0.5 Tesla) ... T cell content of the ...
... 20 cm, is used for vertical slab gel ... gels. The cell is supplied without spacers and ... with gaskets, lower buffer chamber, lid with cables, ... upper buffer dam, casting stand with gaskets, leveling ...
...
Biology Products: